Literature DB >> 1422200

Melas: an original case and clinical criteria for diagnosis.

M Hirano1, E Ricci, M R Koenigsberger, R Defendini, S G Pavlakis, D C DeVivo, S DiMauro, L P Rowland.   

Abstract

We describe the full history and postmortem findings in one of the first identified cases of mitochondrial encephalomyopathy with stroke-like episodes (MELAS). To clarify diagnostic criteria, we analyzed 69 reported cases. The syndrome should be suspected by the following three invariant criteria: (1) stroke-like episode before age 40 yr; (2) encephalopathy characterized by seizures, dementia, or both; and (3) lactic acidosis, ragged-red fibers (RRF), or both. The diagnosis may be considered secure if there are also at least two of the following: normal early development, recurrent headache, or recurrent vomiting. There are incomplete syndromes in relatives of patients with the full syndrome and incomplete syndromes might also be encountered in sporadic cases. Some MELAS patients have features of the Kearns-Sayre syndrome (KSS) or myoclonic epilepsy with ragged-red fibers (MERRF), but none had the full KSS syndrome. In partial or confusing cases, analysis of mitochondrial DNA (mtDNA) may point to the correct diagnosis; however, not all patients with clinical MELAS have had the typical mtDNA point mutation and some patients with the mutation have clinical syndromes other than MELAS.

Entities:  

Mesh:

Year:  1992        PMID: 1422200     DOI: 10.1016/0960-8966(92)90045-8

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  89 in total

Review 1.  Clinical mitochondrial genetics.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-06       Impact factor: 6.318

2.  Diagnosis of mitochondrial disorders applying massive pyrosequencing.

Authors:  Marcelo Andrés Kauffman; Dolores Gonzlez-Morón; Damián Consalvo; Gastón Westergaard; Martín Vazquez; Estefanía Mancini; Ana Lía Taratuto; Raúl Rey; Silvia Kochen
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

3.  A novel tRNA(Val) mitochondrial DNA mutation causing MELAS.

Authors:  Kurenai Tanji; Petra Kaufmann; Ali B Naini; Jiesheng Lu; Timothy C Parsons; Dong Wang; Joshua Z Willey; Sara Shanske; Michio Hirano; Eduardo Bonilla; Alexander Khandji; Salvatore Dimauro; Lewis P Rowland
Journal:  J Neurol Sci       Date:  2008-03-07       Impact factor: 3.181

Review 4.  Multisystem manifestations of mitochondrial disorders.

Authors:  Stefano Di Donato
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

Review 5.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

6.  Mitochondrial encephalomyopathies--fifty years on: the Robert Wartenberg Lecture.

Authors:  Salvatore DiMauro
Journal:  Neurology       Date:  2013-07-16       Impact factor: 9.910

Review 7.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

Review 8.  The neuro-ophthalmology of mitochondrial disease.

Authors:  J Alexander Fraser; Valérie Biousse; Nancy J Newman
Journal:  Surv Ophthalmol       Date:  2010-05-14       Impact factor: 6.048

9.  Intracellular heteroplasmy for disease-associated point mutations in mtDNA: implications for disease expression and evidence for mitotic segregation of heteroplasmic units of mtDNA.

Authors:  P M Matthews; R M Brown; K Morten; D Marchington; J Poulton; G Brown
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

10.  The nuclear background influences the penetrance of the near-homoplasmic m.1630 A > G MELAS variant in a symptomatic proband and asymptomatic mother.

Authors:  Martine Uittenbogaard; Hao Wang; Victor Wei Zhang; Lee-Jun Wong; Christine A Brantner; Andrea Gropman; Anne Chiaramello
Journal:  Mol Genet Metab       Date:  2019-01-25       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.